

## Management Certification

The undersigned, on behalf of Brainstorm Cell Therapeutics Inc. ("the Company"), certifies that the information provided herein is accurate and complete to the best of the Company's knowledge.

1. The Company is current in its disclosure obligations pursuant to the following reporting standard:

### SEC Reporting Obligations

- ☒ ☐ The Company has a reporting obligation under Section 13 or 15(d) of the Exchange Act
- ☐ The Company has a reporting obligation under Regulation A (Tier 2)
- ☐ The Company has a reporting obligation under Regulation Crowdfunding (CF)
- ☐ Other (please describe)

### Other Reporting Obligations

- ☐ The Company is a U.S. bank, bank holding company, or similar financial institution exempt from SEC registration, has a reporting obligation to a U.S. Bank Regulator and follows OTC Markets' Bank Reporting requirements.
- ☐ The Company is exempt from SEC registration and is reporting under the Alternative Reporting Standard

2. Indicate below whether the Company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☐ No: ☒

3. Indicate below whether the Company is subject to Bankruptcy or reorganization proceedings.

Yes: ☐ No: ☒

4. The Company has a Verified Company Profile on OTCMarkets.com.
5. The Company is duly organized and in good standing under the laws of the state or jurisdiction in which the Company is organized or does business.
6. The Company understands and acknowledges its obligations to report company-related actions pursuant to Exchange Act Rule 10b-17 and FINRA Rule 6490.
7. The Company understands and acknowledges its obligations to publicly disclose material information in a timely manner in accordance with applicable U.S. federal securities laws, including but not limited to Section 10(b) of the Exchange Act and Rule 10b-5 thereunder.
8. The Company's transfer agent and its address are listed below. If the Company acts as its own transfer agent, indicate that by listing the Company and its information in the fields provided.<sup>1</sup>

Transfer Agent: EQUINITI TRUST COMPANY, LLC

Address: 6201 15th Avenue, Brooklyn, NY 11219, USA.

<sup>1</sup> OTCQX, OTCQB, and OTCID companies are required to retain a transfer agent that participates in the Transfer Agent Verified Shares Program. OTCID companies that act as their own transfer agent may submit data directly to OTC Markets.

9. The Company's most recent Annual Report was prepared by:

Below is a list all law firm(s) and attorney(s) (including internal counsel) that acted as the Company's primary legal counsel in preparing its most recent annual report or, if no attorney assisted in preparing the disclosure, the person(s) who prepared the disclosure and their relationship to the Company.

**Primary Legal Counsel: Goodwin Procter LLP.**

The firm served as the Company's primary external legal counsel in connection with SEC reporting obligations, including the preparation and review of the Company's most recent Annual Report.

**Internal Review:**

The Annual Report was also reviewed and coordinated internally by **Alla Patlis, Controller and Interim CFO of Brainstorm Cell Therapeutics Inc.**

10. The Company's Officers, Directors and 5% Beneficial Owners are listed below:

The table below provides information regarding all officers and directors of the Company, or any person that performs a similar function, regardless of the number of shares they own. To the best of the Company's knowledge, it includes all individuals or entities beneficially owning 5% or more of any class of the issuer's equity securities. To identify holders of 5% or more, companies may obtain a recent copy of their shareholder list that includes Non-Objecting Beneficial Owners or "NOBOs." SEC Reporting companies may also research their beneficial ownership and insider transaction filings such as on Schedules 13G or 13D or on Forms 3, 4, and 5.

As of (latest practicable date): April 1, 2025.

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, ≥ 5% beneficial owner)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
Chaim Lebovits	CEO and president	Jerusalem, Israel	Consists of (i)128,919 shares of Common Stock owned by ACCBT Corp. acquired through an investment into the Company and (ii) 4,470 shares of	Common stock	4.93%

			Common Stock owned by ACC International Holdings Ltd., (iii) 24,641 shares of Common Stock issuable to Chaim Lebovits upon the exercise of Presently Exercisable Options and (iv) 200,960 shares of restricted stock. Chaim Lebovits, our Chief Executive Officer, may be deemed the beneficial owner of these shares.		
Alla Patlis	Controller and Interim CFO	Petah Tikwa, Israel	Consists of 44,349 shares of Common Stock.	Common stock	0%
Uri Yablonka	Director and CBO	Tel Aviv, Israel	Consists of 6,222 of shares of Common Stock issuable upon the exercise of Presently Exercisable Options and	Common stock	1.03%

			68,464 shares of restricted stock.		
Ibrahim B. Dagher	CMO	Wellesley, MA	Consists of 79,515 shares of restricted stock and 2,333 issuable upon the exercise of Presently Exercisable Options.	Common stock	1.12%
Hartoun Hartounian	COO	Fort Lee, NJ	Consists of 52,000 shares of restricted stock.	Common stock	0%
Dr. Irit Arbel	Director	Jerusalem, Israel	Consists of 13,511 shares of Common Stock issuable upon the exercise of Presently Exercisable Options and 41,054 shares of restricted stock.	Common stock	0%
Anthony Poverino	Director	Bainbridge Island, WA	Consists of 25,730 shares of restricted stock.	Common stock	0%
Nir Naor	Director	Marietta, GA	0	Common stock	0%
Jacob Frenkel	Director	Tel Aviv, Israel	Consists of 43,777 shares of Common Stock owned prior to	Common stock	0%

			joining the board and 10,000 issuable upon the exercise of Presently Exercisable Options.		
Menghisteab Bairu	Director	San Mateo, CA	Consists of 24,000 shares of restricted stock.	Common stock	0%
Dr. Stacy Lindborg	Director	Lexington, MA	44,146 shares	Common stock	0%
				Common stock	0%

Any additional material details, including conversion terms of any class of the issuer's equity securities, are below:

The percentage of the Common Stock beneficially owned by each person or entity named in the following table is based on 7,253,821 shares of Common Stock outstanding as of April 1, 2025, plus any shares issuable upon exercise of Presently Exercisable Options and Presently Exercisable Warrants held by such person or entity.

The Company has Convertible Debt as detailed below:

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

☒ Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion <sup>2</sup>	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)

Total Outstanding Balance:

Total Shares:

Any additional material details, including footnotes to the table are below :

<sup>2</sup> The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

**Signature:**

Name of Principal Executive Officer or Principal Financial Officer: Alla Patlis

Title: Controller and Interim CFO

Date: July 14, 2025

Signature: Alla Patlis

(Digital Signatures should appear as "/s/ [OFFICER NAME]")